Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide and dexamethasone for acute myeloma light-chain induced renal failure
2008-006497-15Phase 2Completed
- Sponsor
- Wilhelminen Cancer Research Institute
- Start
- Nov 2008
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenalidomide and dexamethasone in multiple myeloma (MM) and acute kidney failure (AKF), sponsored by Wilhelminen Cancer Research Institute. Primary endpoints: Overall hematologic response rate and Renal response rate. Started Nov 2008; status: completed.
02
Drugs
lenalidomidedexamethasone
03
Conditions
multiple myeloma (MM)acute kidney failure (AKF)
Beyond the preview
Go deeper on 2008-006497-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006497-15.